Cordtz et al. HCQ for COVID-19 PrEP
Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark
et al., Journal of Clinical Medicine,
Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study..
Journal of Clinical Medicine, doi:10.3390/jcm10173842
Retrospective 2,533 SLE patients in Denmark showing no significant difference in hospitalization risk for COVID-19 cases with HCQ treatment.
risk of hospitalization, , treatment 1,170, control 1,363, adjusted per study.
40.0% lower, HR 0.60, p = 0.39
Effect extraction follows
pre-specified rules prioritizing more serious outcomes. Submit updates
Cordtz et al., 27 Aug 2021, retrospective, population-based cohort, Denmark, peer-reviewed, 8 authors, study period 1 March, 2020 - 2 February, 2021.
Abstract: Journal of
Incidence of COVID-19 Hospitalisation in Patients with
Systemic Lupus Erythematosus: A Nationwide Cohort Study
René Cordtz 1,2, *,† , Salome Kristensen 1,3,† , Louise Plank Holm Dalgaard 1 , Rasmus Westermann 1 ,
Kirsten Duch 1,4 , Jesper Lindhardsen 5 , Christian Torp-Pedersen 6,7 and Lene Dreyer 1,2,3
Department of Rheumatology, Aalborg University Hospital, 9000 Aalborg, Denmark; email@example.com (S.K.);
firstname.lastname@example.org (L.P.H.D.); email@example.com (R.W.); firstname.lastname@example.org (K.D.); email@example.com (L.D.)
Department of Rheumatology, Center for Rheumatology and Spine Diseases, Gentofte Hospital,
2900 Hellerup, Denmark
Department of Clinical Medicine, Aalborg University, 9000 Aalborg, Denmark
Unit of Clinical Biostatistics, Aalborg University Hospital, 9000 Aalborg, Denmark
Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet,
2100 Copenhagen, Denmark; firstname.lastname@example.org
Department of Cardiology, Nordsjællands Hospital, 3400 Hillerod, Denmark;
Department of Public Health, University of Copenhagen, 1014 Copenhagen, Denmark
Shared first authorship/contributed equally.
Citation: Cordtz, R.; Kristensen, S.;
Dalgaard, L.P.H.; Westermann, R.;
Duch, K.; Lindhardsen, J.;
Torp-Pedersen, C.; Dreyer, L.
Incidence of COVID-19
Hospitalisation in Patients with
Systemic Lupus Erythematosus: A
Nationwide Cohort Study from
Denmark. J. Clin. Med. 2021, 10, 3842.
Academic Editors: Christopher
Sjöwall and Ioannis Parodis
Received: 30 July 2021
Accepted: 23 August 2021
Published: 27 August 2021
Abstract: Background: Patients with systemic lupus erythematosus (SLE) have an increased risk of
infections due to impaired immune functions, disease activity, and treatment. This study investigated
the impact of having SLE on the incidence of hospitalisation with COVID-19 infection. Methods:
This was a nationwide cohort study from Denmark between 1 March 2020 to 2 February 2021, based
on the linkage of several nationwide registers. The adjusted incidence of COVID-19 hospitalisation
was estimated for patients with SLE compared with the general population in Cox-regression models.
Among SLE patients, the hazard ratio (HR) for hospitalisation was analysed as nested case-control
study. Results: Sixteen of the 2533 SLE patients were hospitalised with COVID-19 infection. The
age-sex adjusted rate per 1000 person years was 6.16 (95% CI 3.76–10.08) in SLE patients, and the
corresponding hazard ratio was 2.54 (95% CI 1.55–4.16) compared with the matched general population group after adjustment for comorbidities. Among SLE patients, hydroxychloroquine treatment
was associated with a HR for hospitalisation of 0.61 (95% CI 0.19–1.88), and 1.06 (95% CI 0.3–3.72)
for glucocorticoid treatment. Conclusion: Patients with SLE were at increased risk of hospitalisation
Keywords: systemic lupus erythematosus; COVID-19; hydroxychloroquine; glucocorticoids
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
provide treatment protocols.